Gut Runs Fact-Check Before Alerting Brain

You get sick. You feel terrible. You stop eating. Standard biology textbook stuff — or so it seemed.

David Julius, who won the 2021 Nobel Prize in Physiology or Medicine for figuring out how the body senses heat and pain, has just published a paper in Nature with Richard Locksley, an immunologist at the University of California, San Francisco, that makes the whole story considerably stranger. The gut, it turns out, does not simply report damage upward and let the brain decide. It runs its own fact-check first. And the delay between eating something contaminated and losing your appetite is not a slow pipeline — it is a deliberate two-step verification system, purpose-built to confirm a genuine threat before bothering the boss.

The March 25 paper, published in Nature, describes what the team calls a dedicated gut-to-brain circuit for anorexia during infection. The first step begins when tuft cells — rare sensory cells scattered throughout the intestinal lining — detect succinate, a molecule produced by parasitic worms. The tuft cells respond by releasing acetylcholine. This is already odd, because tuft cells lack the synaptic vesicles and excitable membranes that neurons normally require to release neurotransmitters. They synthesize acetylcholine via the enzyme Chat but have none of the usual cellular machinery for controlled release, as the paper notes. They release it anyway, through a mechanism the team is still characterizing.

The acetylcholine activates neighboring enterochromaffin cells — the same gut cells that produce most of the body's serotonin. When stimulated, enterochromaffin cells dump serotonin onto vagal nerve fibers, which carry the signal directly to the brainstem, as Neuroscience News reported. Not to immune cells. Not to the hypothalamus via the bloodstream. Straight to the vagus, the same route the gut uses to signal nausea and satiety.

Koki Tohara, a postdoctoral researcher at UCSF and the paper's first author, found the answer by placing genetically engineered sensor cells next to tuft cells under a microscope and watching acetylcholine release in real time. The cells released it in two distinct phases, as Genetic Engineering News reported: an acute burst when they first encountered parasite-derived metabolites, and a sustained leak-like release that accompanied the type 2 inflammation that follows a live infection. Only the sustained phase produced serotonin levels sufficient to activate the vagal appetite circuits.

In mice, the effect was precise: animals with intact tuft cell function ate less during parasitic infection, while mice engineered to lack acetylcholine-producing machinery in tuft cells continued eating normally, as UCSF reported. "The gut is essentially waiting to confirm that the threat is real and persistent before it tells the brain to change your behavior," the university quoted Julius as saying.

This is the counterintuitive part. The anorexia of infection is not a bug in the response system — it is the feature. The gut fact-checks. It says: we have a parasite here, confirmed, and it is not leaving on its own. Therefore, food intake should stop. The standard sickness-behavior pathway — cytokines from activated immune cells traveling to the hypothalamus — works fine for systemic illness. But for a localized gut infection, the tuft cell circuit is a dedicated hotline, and it does not trigger until the inflammatory response confirms the problem is ongoing.

Disruptions in this pathway may contribute to irritable bowel syndrome, food intolerances, and chronic visceral pain, according to SciTech Daily. If the sustained-release phase fires inappropriately, it could produce appetite suppression without an actual infection. If it fails to fire, it might explain why some people experience chronic gut hypersensitivity without an obvious trigger.

The translational angle is tuft cells as drug targets. A compound that selectively enhances the sustained acetylcholine release phase might make parasitic infection anorexia more effective. A compound that suppresses it might calm the circuit in IBS. The mechanism is specific and local — it does not touch the broader immune response the way cytokine-targeting drugs do. That specificity is what makes it interesting as a pharmaceutical target.

The study was done in collaboration with Stuart Brierly and his lab at the University of Adelaide in Australia, as Genetic Engineering News noted. Funding came from the National Institutes of Health and the BRAIN Initiative.

The paper — doi: 10.1038/s41586-026-10281-5 — appears in the March 25, 2026 issue of Nature.

For biotech readers, the immediate implication is not "here is another gut mechanism to drug." It is that this circuit is unusually clean — two cell types, one neurotransmitter cascade, a dedicated nerve tract, and a clear behavioral output. That makes it a better target than it might first appear. The body does not usually build dedicated wiring for single behavioral states. When it does, it is worth paying attention to what the wire is for — and in this case, it is for not eating while parasitized. Which, the paper quietly suggests, is a feature the body evolved to want.